Oncaspar(pegaspargase)
Oncaspar (pegaspargase) is an enzyme pharmaceutical. Pegaspargase was first approved as Oncaspar on 1994-02-01. It is used to treat b-cell chronic lymphocytic leukemia, blast crisis, non-hodgkin lymphoma, and precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma.
Download report
Favorite
Drugs Approved for Childhood Cancers
Commercial
Trade Name
FDA
EMA
Oncaspar
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Pegaspargase
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Oncaspar | pegaspargase | Servier | N-103411 RX | 1994-02-01 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| oncaspar | Biologic Licensing Application | 2020-11-25 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
pegaspargase, Oncaspar, Servier Pharmaceuticals LLC | |||
| 2101-02-01 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9266 | Injection, pegaspargase, per single dose vial |
Clinical
Clinical Trials
151 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 2 | — | — | — | 3 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | 2 | — | — | — | 3 | |
| Biphenotypic leukemia acute | D015456 | C95.0 | — | 3 | — | — | — | 3 | |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | 3 | 1 | — | — | — | 3 | ||
| Inborn genetic diseases | D030342 | EFO_0000508 | — | 1 | — | — | — | 1 | |
| B-cell leukemia | D015448 | — | 1 | — | — | — | 1 | ||
| Precursor b-cell lymphoblastic leukemia-lymphoma | D015452 | 1 | 1 | — | — | — | 1 | ||
| Multiple myeloma | D009101 | C90.0 | — | 1 | — | — | — | 1 | |
| Hodgkin disease | D006689 | C81 | — | 1 | — | — | — | 1 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PEGASPARGASE |
| INN | pegaspargase |
| Description | Pegaspargase, sold under the brand name Oncaspar, is a medication used in the treatment of acute lymphoblastic leukemia (ALL). Often it is used together with anthracycline, vincristine, and corticosteroids (for example prednisone and dexamethasone). Pegaspargase can be administered either via an intravenous infusion or a intramuscular injection.
|
| Classification | Enzyme |
| Drug class | enzymes; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 130167-69-0 |
| RxCUI | 34132 |
| ChEMBL ID | CHEMBL2108546 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00059 |
| UNII ID | 7D96IR0PPM (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,144 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,655 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more